IL281362A - Formulations of glucagon-like-peptide-2 (glp-2) analogues - Google Patents
Formulations of glucagon-like-peptide-2 (glp-2) analoguesInfo
- Publication number
- IL281362A IL281362A IL281362A IL28136221A IL281362A IL 281362 A IL281362 A IL 281362A IL 281362 A IL281362 A IL 281362A IL 28136221 A IL28136221 A IL 28136221A IL 281362 A IL281362 A IL 281362A
- Authority
- IL
- Israel
- Prior art keywords
- glp
- glucagon
- analogs
- peptide
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197755.4A EP3628683A1 (en) | 2018-09-28 | 2018-09-28 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| PCT/EP2019/076305 WO2020065064A1 (en) | 2018-09-28 | 2019-09-27 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL281362A true IL281362A (en) | 2021-04-29 |
Family
ID=63794308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL281362A IL281362A (en) | 2018-09-28 | 2021-03-09 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220265551A1 (enExample) |
| EP (2) | EP3628683A1 (enExample) |
| JP (2) | JP7566730B2 (enExample) |
| KR (1) | KR20210069056A (enExample) |
| CN (3) | CN112771073B (enExample) |
| AU (1) | AU2019348538B2 (enExample) |
| BR (1) | BR112021005858A2 (enExample) |
| CA (1) | CA3114330A1 (enExample) |
| CL (1) | CL2021000678A1 (enExample) |
| IL (1) | IL281362A (enExample) |
| MX (1) | MX2021003271A (enExample) |
| SG (1) | SG11202102383VA (enExample) |
| WO (1) | WO2020065064A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2894629T3 (es) | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| CA3179472A1 (en) * | 2020-05-22 | 2021-11-25 | Sung Hee Hong | Liquid formulation of long-acting conjugate of glp-2 |
| WO2022129142A1 (en) * | 2020-12-16 | 2022-06-23 | Zealand Pharma A/S | Use of glp-2 analogues in patients with renal insufficiency |
| CA3231402A1 (en) * | 2021-09-10 | 2023-03-16 | Eva Horn Moller | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| IL319890A (en) | 2022-09-30 | 2025-05-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| WO2024075135A1 (en) * | 2022-10-03 | 2024-04-11 | Orbicular Pharmaceutical Technologies Private Limited | "stable injectable compositions of glp-2 peptide" |
| AU2024212236A1 (en) | 2023-01-27 | 2025-08-28 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| TW202535919A (zh) * | 2023-12-28 | 2025-09-16 | 丹麥商西蘭製藥公司 | 類升糖素肽2(glp-2)類似物之調配物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| EP1231219B1 (en) | 1996-04-12 | 2010-08-25 | 1149336 Ontario Inc. | GLucagon-like peptide-2 analogs |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US7112567B2 (en) | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| EP2119725A1 (en) * | 2005-05-03 | 2009-11-18 | Novetide Ltd. | Methods for the production of leuprolide |
| AU2006242998B2 (en) * | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| JP2009521213A (ja) * | 2005-12-24 | 2009-06-04 | ティーガスク デイリー プロダクツ リサーチ センター | トランス−１０，シス−１２オクタデカジエン酸を製造する方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| EP2051995B1 (en) * | 2006-11-08 | 2017-02-08 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| AU2007340369C1 (en) * | 2006-12-29 | 2013-05-02 | Ipsen Pharma S.A.S. | GLP-1 pharmaceutical compositions |
| MX2012013375A (es) * | 2010-05-17 | 2013-04-11 | Cebix Inc | Peptido c pegilado. |
| FR2994390B1 (fr) * | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| HUE032392T2 (en) * | 2012-11-20 | 2017-09-28 | Fresenius Kabi Usa Llc | Kaszpofunginacetát compositions |
| EP3209332B1 (en) * | 2014-10-23 | 2021-05-26 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| WO2018094404A1 (en) * | 2016-11-21 | 2018-05-24 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
-
2018
- 2018-09-28 EP EP18197755.4A patent/EP3628683A1/en not_active Withdrawn
-
2019
- 2019-09-27 CN CN201980063594.1A patent/CN112771073B/zh active Active
- 2019-09-27 JP JP2021517294A patent/JP7566730B2/ja active Active
- 2019-09-27 CN CN202510255078.6A patent/CN120204366A/zh active Pending
- 2019-09-27 US US17/276,252 patent/US20220265551A1/en active Pending
- 2019-09-27 AU AU2019348538A patent/AU2019348538B2/en active Active
- 2019-09-27 MX MX2021003271A patent/MX2021003271A/es unknown
- 2019-09-27 CN CN202410277209.6A patent/CN118267455A/zh active Pending
- 2019-09-27 EP EP19773860.2A patent/EP3856766A1/en active Pending
- 2019-09-27 KR KR1020217010775A patent/KR20210069056A/ko not_active Ceased
- 2019-09-27 CA CA3114330A patent/CA3114330A1/en active Pending
- 2019-09-27 WO PCT/EP2019/076305 patent/WO2020065064A1/en not_active Ceased
- 2019-09-27 BR BR112021005858-3A patent/BR112021005858A2/pt unknown
- 2019-09-27 SG SG11202102383VA patent/SG11202102383VA/en unknown
-
2021
- 2021-03-09 IL IL281362A patent/IL281362A/en unknown
- 2021-03-19 CL CL2021000678A patent/CL2021000678A1/es unknown
-
2023
- 2023-10-16 US US18/487,666 patent/US20240065978A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120747A patent/JP7738136B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202102383VA (en) | 2021-04-29 |
| CN118267455A (zh) | 2024-07-02 |
| US20220265551A1 (en) | 2022-08-25 |
| AU2019348538A1 (en) | 2021-05-20 |
| JP2022502432A (ja) | 2022-01-11 |
| CN112771073B (zh) | 2025-07-01 |
| CN112771073A (zh) | 2021-05-07 |
| JP7566730B2 (ja) | 2024-10-15 |
| EP3856766A1 (en) | 2021-08-04 |
| MX2021003271A (es) | 2021-05-12 |
| JP7738136B2 (ja) | 2025-09-11 |
| AU2019348538B2 (en) | 2025-04-03 |
| EP3628683A1 (en) | 2020-04-01 |
| BR112021005858A2 (pt) | 2021-07-27 |
| WO2020065064A1 (en) | 2020-04-02 |
| JP2024156754A (ja) | 2024-11-06 |
| KR20210069056A (ko) | 2021-06-10 |
| CA3114330A1 (en) | 2020-04-02 |
| CL2021000678A1 (es) | 2021-08-06 |
| CN120204366A (zh) | 2025-06-27 |
| US20240065978A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281362A (en) | Formulations of glucagon-like-peptide-2 (glp-2) analogues | |
| DK3881861T3 (da) | Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger | |
| IL283134A (en) | Alcohol-resistant drug formulations | |
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| MA54407A (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
| EP4045480A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK4122954T3 (da) | Novel GLP-1-analoger | |
| HRP20190388T1 (hr) | Eksendin-4 derivati kao peptidni dvostruki agonisti receptora glp-1 / glukagona | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| EP3615079A4 (en) | STABLE CANNABINOID FORMULATIONS | |
| EP4233846C0 (en) | PHARMACEUTICAL FORMULATIONS | |
| DK3541366T3 (da) | Bufferformuleringer af exendin (9-39) | |
| ZA202001888B (en) | Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative | |
| LT3793587T (lt) | Pradinė pth konjugatų dozė | |
| DK3886820T3 (da) | Kapselformuleringer | |
| IL285674A (en) | Pharmaceutical formulations | |
| EP3394091A4 (en) | CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | |
| EP3785698A4 (en) | Edaravone pharmaceutical composition | |
| EP3583943A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP3830103C0 (en) | FLUORINATED BILE ACID DERIVATIVES | |
| EP3600279A4 (en) | 1-amino-1-cyclopropanecaboxylic acid formulations | |
| HUE063178T2 (hu) | Kopanlizib formulációi | |
| EP3868371A4 (en) | Novel pharmaceutical composition | |
| SI3512495T1 (sl) | Formulacije prostaciklinskih analogov |